Our Partners

Thank you to our partners

To discuss Corporate Partnerships, unique fundraising ideas, more about the Walk, and other ways you can be involved please email our Event Director or call 866-PUW-WALK (789-9255).

Sponsors for the 2014 Walk:


    AbbVie is dedicated to being a partner and champion in the fight against Parkinson’s and we are pleased to join you in support of the 2014 Parkinson’s Unity Walk. AbbVie is committed to improving the lives of those with Parkinson’s and we look forward to continuing our work with the Parkinson’s community to help raise awareness of this disease and funds for research. Thank you to everyone that is working together in the fight for a better future in Parkinson’s.  Read more.




Teva CNS is committed to the continued research and development of its product portfolio and to the development of medicines aimed at meeting the specific needs of the patient communities it serves. Teva’s legacy in CNS is grounded in its commitment to ongoing collaboration with academia, medical institutions and patient advocacy groups to find innovative solutions for patients who live with chronic and debilitating diseases, such as Parkinson’s disease. Read more.
At UCB, we have a passionate, long-term commitment to discovering and developing innovative medicines that transform the lives of people living with severe immunological diseases and central nervous system disorders. With 8,500 employees in 40 countries, we invest more than 25% of revenue in cutting-edge scientific research to meet unmet patient needs. Read more.
At US WorldMeds, we hold a fundamental belief that our science has the potential to improve the lives of Parkinson’s patients. US WorldMeds’ commitment to Parkinson’s patients is reflected in all that we do. Our pipeline of development projects, along with our currently available PD treatment, reflects our resolve to bring innovative solutions to Parkinson’s patients.  Read more.    




Boston Scientific’s VerciseTM Deep Brain Stimulation (DBS) system provides therapy that helps reduce some of the symptoms associated with Parkinson’s disease. DBS utilizes a surgically implanted medical device that works by stimulating a targeted area in the brain. The stimulation can be adjusted by your physician to optimize your therapy to help control your symptoms.  Read more.

  Chelsea Therapeutics is a biopharmaceutical company that specializes in the development of innovative products that address important unmet medical needs or offer alternatives to current treatments. Read more.
LSVT Global is a socially responsible business with a mission to empower people with Parkinson disease (PD) through evidence-based speech, physical and occupational therapy programs. LSVT Global seeks to translate clinical treatment research directly to public health practice and increase accessibility of LSVT to people living with PD.  Read more.    DBS therapy uses a surgically implanted medical device, similar to a pacemaker, to deliver mild electrical pulses to precisely targeted areas of the brain. The stimulation can be programmed and adjusted non-invasively by a trained clinician to maximize symptom control and minimize side effects. More than 100,000 patients worldwide have received Medtronic DBS Therapy  Read more.
MRI Interventions, Inc. is the developer of a minimally invasive neurosurgical platform, the ClearPoint® system, that enables “asleep” deep brain stimulation (DBS) lead placement. ClearPoint technology allows patients to experience a frameless DBS procedure, to sleep throughout the entire procedure, and to continue regular medications through surgery. DBS surgery with the ClearPoint system may also involve fewer hospital visits for patients.  Read more.    




The Tuchman Foundation/



The Kenneth Aidekman Family Foundation





We also thank:

City of New York Parks & Recreation and The New York City Police Department